{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Nervous+System+Disorder",
    "query": {
      "condition": "Autoimmune Nervous System Disorder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1711,
    "total_pages": 172,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Autoimmune+Nervous+System+Disorder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:55:28.025Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03586986",
      "title": "Risk Factors in Early Multiple Sclerosis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Magnetic Resonance Imaging",
        "Biomarkers",
        "Clinically Isolated Syndrome",
        "Radiologically Isolated Syndrome"
      ],
      "interventions": [
        {
          "name": "Brain MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 300,
      "start_date": "2018-07-26",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03586986"
    },
    {
      "nct_id": "NCT05442112",
      "title": "Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Wellness Patient Message",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 51,
      "start_date": "2023-06-11",
      "completion_date": "2024-05-11",
      "has_results": false,
      "last_update_posted_date": "2024-05-17",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05442112"
    },
    {
      "nct_id": "NCT02269930",
      "title": "Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "peginterferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Rebif",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-02",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269930"
    },
    {
      "nct_id": "NCT03835728",
      "title": "Efficacy of Ocrelizumab in Autoimmune Encephalitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Encephalitis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2019-01-22",
      "completion_date": "2020-10-02",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03835728"
    },
    {
      "nct_id": "NCT01874145",
      "title": "Safety and Tolerability of Glatiramer Acetate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "GA 20 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "GA 40 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2013-06",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 35,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874145"
    },
    {
      "nct_id": "NCT03562975",
      "title": "Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Pathologic Processes",
        "Demyelinating Diseases",
        "Nervous System Diseases",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Primary Progressive Multiple Sclerosis",
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-07-23",
      "completion_date": "2023-01-11",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03562975"
    },
    {
      "nct_id": "NCT06981013",
      "title": "Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "balance based torso weighting",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of St. Augustine for Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-03-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Saint Augustine, Florida",
      "locations": [
        {
          "city": "Saint Augustine",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06981013"
    },
    {
      "nct_id": "NCT02651545",
      "title": "Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-02",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-09-24",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651545"
    },
    {
      "nct_id": "NCT02465359",
      "title": "Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Subcutaneous (Human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-09",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465359"
    },
    {
      "nct_id": "NCT06083753",
      "title": "Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "PIPE-307 Dose A",
          "type": "DRUG"
        },
        {
          "name": "PIPE-307 Dose B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Contineum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 182,
      "start_date": "2023-11-06",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-05-21T22:55:28.025Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Colorado Springs, Colorado + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06083753"
    }
  ]
}